Current status of immunotherapy for advanced gastric cancer

被引：46

作者：

Kawazoe, Akihito ^{[1
]}

Shitara, Kohei ^{[1
]}

Boku, Narikazu ^{[2
]}

Yoshikawa, Takaki ^{[3
]}

Terashima, Masanori ^{[4
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Med Oncol, Chiba, Japan

[2] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[3] Natl Canc Ctr, Dept Gastr Surg, Tokyo, Japan

[4] Shizuoka Canc Ctr, Div Gastr Surg, Nagaizumi, Shizuoka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 51卷 / 01期

关键词：

gastric cancer; immunotherapy; immune checkpoint inhibitors; clinical trials; predictive biomarkers; combination therapies; GASTROESOPHAGEAL JUNCTION CANCER; REGULATORY T-CELLS; MISMATCH-REPAIR; SINGLE-ARM; OPEN-LABEL; 1ST-LINE TREATMENT; RESPONSE RATES; PD-1; BLOCKADE; DOUBLE-BLIND; LUNG-CANCER;

D O I：

10.1093/jjco/hyaa202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies have improved the overall survival of various types of cancers including advanced gastric cancer (AGC). Until now, two ant-PD-1 inhibitors were approved for AGC in Japan: nivolumab as third- or later-line treatment for AGC and pembrolizumab for previously treated patients with microsatellite instability-high tumours. However, a limited number of patients achieved clinical benefit, highlighting the importance of the better selection of patients or additional treatment to overcome resistance to PD-1/PD-L1 blockade. This review focused on pivotal clinical trials, biomarkers and novel combination therapy of immune checkpoint inhibitors for AGC.

引用

页码：20 / 27

页数：8

共 50 条

[11] Immunotherapy for gastric cancer: Advances and challenges
Zhang, Pei
Zhang, Chenyan
Li, Xiaoying
Chang, Chen
Gan, Cailing
Ye, Tinghong
Cao, Dan
MEDCOMM-ONCOLOGY, 2024, 3 (04):
[12] Current status of neoadjuvant immunotherapy for the treatment of gastric cancer
Zhang, Xijie
Liu, Bo
Wang, Rui
Li, Xin
Zhou, Wence
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09): : 2097 - 2108
[13] Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
Cho, Ju Hwan
IMMUNE NETWORK, 2017, 17 (06) : 378 - 391
[14] Recent advances in immunotherapy and molecular targeted therapy for gastric cancer
Yoshinami, Yuri
Shoji, Hirokazu
FUTURE SCIENCE OA, 2023, 9 (02):
[15] Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
Kono, Koji
Nakajima, Shotaro
Mimura, Kosaku
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (7) : 865 - 872
[16] Predictive response and outcome of peripheral CD4+T cell subpopulations to combined immunotherapy and chemotherapy in advanced gastric cancer patients
Gao, Deyu
Liu, Liqiong
Liu, Jianhua
Liu, Jiang
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 129
[17] Immunology and immunotherapy in gastric cancer
Xu, Xiaqing
Chen, Jiaxing
Li, Wenxing
Feng, Chenlu
Liu, Qian
Gao, Wenfang
He, Meng
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3189 - 3204
[18] Current and Future Therapies for Advanced Gastric Cancer
Davidson, Michael
Okines, Alicia F. C.
Starling, Naureen
CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 239 - 250
[19] Targeted and immunotherapy in the era of personalised gastric cancer treatment
Catanese, Silvia
Lordick, Florian
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2021, 50-51
[20] Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway
Cheng, Runzi
Li, Baizhi
Wang, Huaiming
Zeng, Yongming
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (11): : 3122 - 3138

← 1 2 3 4 5 →